In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Abstract The international American Joint Committee on Cancer/Union for International
Cancer Control (AJCC/UICC) tumour-node-metastasis (TNM) staging system provides the …

Background The use of immune checkpoint inhibitors (ICIs) has become standard therapy in
many tumor sites. The aim of this study is to systematically review the literature to determine …

Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …

Cancer growth and progression are associated with immune suppression. Cancer cells
have the ability to activate different immune checkpoint pathways that harbor …

Lung cancer remains the leading cause of cancer deaths in the United States. In the past
decade, significant advances have been made in the science of non–small cell lung cancer …

The immune system is critical in modulating cancer progression, but knowledge of immune
composition, phenotype, and interactions with tumor is limited. We used multiplexed ion …

In lung cancer, enrichment of the lower airway microbiota with oral commensals commonly
occurs, and ex vivo models support that some of these bacteria can trigger host …

Tumors responding to immune checkpoint inhibitors (ICIs) have a higher level of immune
infiltrates and/or an Interferon (IFN) signature indicative of a T-cell-inflamed phenotype …

Oncolytic viruses can be usefully integrated into tumour immunotherapies, as they target
multiple steps within the cancer–immunity cycle. Oncolytic viruses directly lyse tumour cells …